CDC: Physicians should confirm patients’ penicillin allergies

New research from the U.S. Center for Disease Control and Prevention (CDC) points to evidence that many patients who claim they have a penicillin allergy may actually not have one.

Right now, about 30 million people would say they are allergic to penicillin, which can be dangerous when physicians are looking for alternative antibiotics to give them. Some of those alternative medications can be more toxic and carry higher rates of infections and morbidity.

The CDC is suggesting that physicians evaluate patients who say they have a penicillin allergy, which is about 10 percent of U.S. hospital patients, and test to see if they really have it. Studies show that less than 1 percent of Americans are allergic to penicillin.

"Some patients who report penicillin allergies may never have had true allergies,” said CDC epidemiologist Katherine Fleming-Dutra, MD, in a statement. “They may have had side effects or a symptom of the underlying illness that was interpreted as an allergy, such as a viral exanthema or rash in a child on amoxicillin.”

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.